Flunitrazepam

More than a date rape drug

Vaughn I. Rickert, Constance M. Wiemann, Abbey Berenson

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Study Objective: To evaluate the independent relationship between depressive symptoms, self-esteem, and drug resistance self-efficacy, and future intentions to use flunitrazepam. Design: Cross-sectional survey. Setting: Community-based family planning clinics. Participants: 865 sexually active women who self-identified as Caucasian, African-American, or Mexican American, denied using flunitrazepam in the last 12 months and reported intentions to use or not use this substance in the next 12 months. Interventions: None. Main Outcome Measure: An anonymous self-report measure assessed the patient's intentions to use flunitrazepam in the next 12 months; other lifetime drug use; and standardized measures of depression, self-esteem, and drug resistance self-efficacy. We hypothesized that future potential users of flunitrazepam would exhibit an increased number of depressive symptoms, lowered self-esteem, and limited drug resistance self-efficacy. Results: Of the 865 subjects, 16 (1.8%) reported using flunitrazepam in their lifetime but not in the last 12 months, and 46 (5.3%) were identified as potential users. Logistic regression analyses controlling for confounding factors found that potential to use flunitrazepam was significantly associated with limited drug resistance self-efficacy (adjusted odds ratio [AOR] = 9.3) and the presence of both severe depressive symptoms and lowered self-esteem (AOR = 3.2). Conclusions: These data suggest that young women with severe depressive symptoms and diminished self-esteem are at high risk for future flunitrazepam use and may use this drug to self-medicate psychological distress.

Original languageEnglish (US)
Pages (from-to)37-42
Number of pages6
JournalJournal of Pediatric and Adolescent Gynecology
Volume13
Issue number1
DOIs
StatePublished - Feb 2000

Fingerprint

Flunitrazepam
Rape
Self Concept
Self Efficacy
Drug Resistance
Depression
Pharmaceutical Preparations
Odds Ratio
Family Planning Services
African Americans
Self Report
Cross-Sectional Studies
Logistic Models
Regression Analysis
Outcome Assessment (Health Care)
Psychology

Keywords

  • Depressive symptoms
  • Drug resistance self-efficacy
  • Flunitrazepam
  • Self medication

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pediatrics, Perinatology, and Child Health

Cite this

Flunitrazepam : More than a date rape drug. / Rickert, Vaughn I.; Wiemann, Constance M.; Berenson, Abbey.

In: Journal of Pediatric and Adolescent Gynecology, Vol. 13, No. 1, 02.2000, p. 37-42.

Research output: Contribution to journalArticle

Rickert, Vaughn I. ; Wiemann, Constance M. ; Berenson, Abbey. / Flunitrazepam : More than a date rape drug. In: Journal of Pediatric and Adolescent Gynecology. 2000 ; Vol. 13, No. 1. pp. 37-42.
@article{4874220888c749a9b6070ab1095bb795,
title = "Flunitrazepam: More than a date rape drug",
abstract = "Study Objective: To evaluate the independent relationship between depressive symptoms, self-esteem, and drug resistance self-efficacy, and future intentions to use flunitrazepam. Design: Cross-sectional survey. Setting: Community-based family planning clinics. Participants: 865 sexually active women who self-identified as Caucasian, African-American, or Mexican American, denied using flunitrazepam in the last 12 months and reported intentions to use or not use this substance in the next 12 months. Interventions: None. Main Outcome Measure: An anonymous self-report measure assessed the patient's intentions to use flunitrazepam in the next 12 months; other lifetime drug use; and standardized measures of depression, self-esteem, and drug resistance self-efficacy. We hypothesized that future potential users of flunitrazepam would exhibit an increased number of depressive symptoms, lowered self-esteem, and limited drug resistance self-efficacy. Results: Of the 865 subjects, 16 (1.8{\%}) reported using flunitrazepam in their lifetime but not in the last 12 months, and 46 (5.3{\%}) were identified as potential users. Logistic regression analyses controlling for confounding factors found that potential to use flunitrazepam was significantly associated with limited drug resistance self-efficacy (adjusted odds ratio [AOR] = 9.3) and the presence of both severe depressive symptoms and lowered self-esteem (AOR = 3.2). Conclusions: These data suggest that young women with severe depressive symptoms and diminished self-esteem are at high risk for future flunitrazepam use and may use this drug to self-medicate psychological distress.",
keywords = "Depressive symptoms, Drug resistance self-efficacy, Flunitrazepam, Self medication",
author = "Rickert, {Vaughn I.} and Wiemann, {Constance M.} and Abbey Berenson",
year = "2000",
month = "2",
doi = "10.1016/S1083-3188(99)00038-8",
language = "English (US)",
volume = "13",
pages = "37--42",
journal = "Journal of Pediatric and Adolescent Gynecology",
issn = "1083-3188",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Flunitrazepam

T2 - More than a date rape drug

AU - Rickert, Vaughn I.

AU - Wiemann, Constance M.

AU - Berenson, Abbey

PY - 2000/2

Y1 - 2000/2

N2 - Study Objective: To evaluate the independent relationship between depressive symptoms, self-esteem, and drug resistance self-efficacy, and future intentions to use flunitrazepam. Design: Cross-sectional survey. Setting: Community-based family planning clinics. Participants: 865 sexually active women who self-identified as Caucasian, African-American, or Mexican American, denied using flunitrazepam in the last 12 months and reported intentions to use or not use this substance in the next 12 months. Interventions: None. Main Outcome Measure: An anonymous self-report measure assessed the patient's intentions to use flunitrazepam in the next 12 months; other lifetime drug use; and standardized measures of depression, self-esteem, and drug resistance self-efficacy. We hypothesized that future potential users of flunitrazepam would exhibit an increased number of depressive symptoms, lowered self-esteem, and limited drug resistance self-efficacy. Results: Of the 865 subjects, 16 (1.8%) reported using flunitrazepam in their lifetime but not in the last 12 months, and 46 (5.3%) were identified as potential users. Logistic regression analyses controlling for confounding factors found that potential to use flunitrazepam was significantly associated with limited drug resistance self-efficacy (adjusted odds ratio [AOR] = 9.3) and the presence of both severe depressive symptoms and lowered self-esteem (AOR = 3.2). Conclusions: These data suggest that young women with severe depressive symptoms and diminished self-esteem are at high risk for future flunitrazepam use and may use this drug to self-medicate psychological distress.

AB - Study Objective: To evaluate the independent relationship between depressive symptoms, self-esteem, and drug resistance self-efficacy, and future intentions to use flunitrazepam. Design: Cross-sectional survey. Setting: Community-based family planning clinics. Participants: 865 sexually active women who self-identified as Caucasian, African-American, or Mexican American, denied using flunitrazepam in the last 12 months and reported intentions to use or not use this substance in the next 12 months. Interventions: None. Main Outcome Measure: An anonymous self-report measure assessed the patient's intentions to use flunitrazepam in the next 12 months; other lifetime drug use; and standardized measures of depression, self-esteem, and drug resistance self-efficacy. We hypothesized that future potential users of flunitrazepam would exhibit an increased number of depressive symptoms, lowered self-esteem, and limited drug resistance self-efficacy. Results: Of the 865 subjects, 16 (1.8%) reported using flunitrazepam in their lifetime but not in the last 12 months, and 46 (5.3%) were identified as potential users. Logistic regression analyses controlling for confounding factors found that potential to use flunitrazepam was significantly associated with limited drug resistance self-efficacy (adjusted odds ratio [AOR] = 9.3) and the presence of both severe depressive symptoms and lowered self-esteem (AOR = 3.2). Conclusions: These data suggest that young women with severe depressive symptoms and diminished self-esteem are at high risk for future flunitrazepam use and may use this drug to self-medicate psychological distress.

KW - Depressive symptoms

KW - Drug resistance self-efficacy

KW - Flunitrazepam

KW - Self medication

UR - http://www.scopus.com/inward/record.url?scp=0033931489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033931489&partnerID=8YFLogxK

U2 - 10.1016/S1083-3188(99)00038-8

DO - 10.1016/S1083-3188(99)00038-8

M3 - Article

VL - 13

SP - 37

EP - 42

JO - Journal of Pediatric and Adolescent Gynecology

JF - Journal of Pediatric and Adolescent Gynecology

SN - 1083-3188

IS - 1

ER -